GPER1 receptor breakthrough could revolutionize psoriasis treatment options

New research highlights the potential of GPER1, a G protein-coupled estrogen receptor, in treating chronic skin inflammation. Studies show it can slow the excessive growth of skin cells linked to conditions like psoriasis. This discovery opens doors for more targeted therapies with fewer side effects than current treatments.

GPER1 works by blocking keratinocyte proliferation, particularly during the G1 phase of the cell cycle. This reduction in cell growth is crucial for managing psoriasis and similar inflammatory skin diseases. Animal tests confirmed that GPER1 agonists eased symptoms and lessened tissue damage in psoriasis-like inflammation.

The receptor also disrupts the MAPK/ERK signalling pathway, lowering levels of inflammatory markers such as TNF-α and IL-6. Unlike traditional estrogen receptors, GPER1 triggers rapid cellular responses, offering a distinct mechanism for controlling inflammation. Scientists suggest this could lead to new topical or systemic treatments tailored to individual patients.

Despite promising preclinical results, no Phase II or III clinical trials for GPER1-based therapies in skin conditions have started as of March 2026. No such studies are listed on major trial registries like ClinicalTrials.gov or EudraCT.

The findings underscore GPER1's potential as a safer, more selective treatment for chronic skin inflammation. Further research will explore how hormonal signals and immune responses interact in the skin. For now, the focus remains on developing and testing GPER1-targeted therapies in human trials.